Showing results (41-50 of 83) with videos related to

Sort By:
Pageof 9
BMC Cancer|February 5, 2013
The relationship of vascular endothelial growth factor gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX: VEGF polymorphism in gastric cancerSung Yong Oh, Hyuk-Chan Kwon, Sung Hyun Kim, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|March 20, 2012
Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancerHyuk-Chan Kwon, Sung Hyun Kim, Sung Yong Oh, et al.
The Korean Journal of Internal Medicine|November 11, 2015
Analysis of factors affecting hemorrhagic diathesis and overall survival in patients with acute promyelocytic leukemiaHo Jin Lee, Dong Hyun Kim, Seul Lee, et al.
American Journal of Clinical Oncology|February 6, 2009
Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancerSung-Hyun Kim, Hyuk-Chan Kwon, Sung Yong Oh, et al.
Cancer Science|April 20, 2010
Clinicopathological significance of nuclear factor-kappa B, HIF-1 alpha, and vascular endothelial growth factor expression in stage III colorectal cancerHyuk-Chan Kwon, Sung Hyun Kim, Sung Yong Oh, et al.
Lung Cancer (Amsterdam, Netherlands)|May 22, 2012
Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapySeok-Hyun Kim, Gyeong-Won Lee, Min Jeong Lee, et al.
World Journal of Gastroenterology|September 25, 2012
Clinicopathologic significance of expression of nuclear factor-κB RelA and its target gene products in gastric cancer patientsHyuk-Chan Kwon, Sung-Hyun Kim, Sung Yong Oh, et al.
The Korean Journal of Hematology|December 2, 2010
A case of subdural hematoma in patient with chronic myeloid leukemia treated with high-dose imatinib mesylateMin Sik Kim, Dong Hyun Lee, Yu Rim Lee, et al.
Cancer Chemotherapy and Pharmacology|February 14, 2015
Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancerIn Gyu Hwang, Joung-Soon Jang, Sung Yong Oh, et al.
Cancers|October 29, 2020
rhEGF Treatment Improves EGFR Inhibitor-Induced Skin Barrier and Immune DefectsJi Min Kim, Jun Ho Ji, Young Saing Kim, et al.
Pageof 9